Diamir Biosciences CORP
New Public Companies (S-1)
DiamiR Biosciences updates its S-1 registration statement to address SEC comments and reflect financials for the quarter ended August 31, 2024, as it prepares for its initial public offering.
Capital raise
DiamiR Biosciences Corp. amends its S-1 registration statement, aiming for a NASDAQ listing to advance its molecular diagnostics for neurodegenerative diseases.
Worse than expected
Capital raise
DiamiR Biosciences Corp. amends its S-1 registration statement to revise disclosures in response to SEC comments for its upcoming IPO.
Worse than expected
Capital raise
DiamiR Biosciences Corp. files an S-1 registration statement for an initial public offering to fund the development and commercialization of blood-based diagnostic tests for neurodegenerative diseases.
Capital raise